{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:16:06Z","timestamp":1794410166168,"version":"4.9.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Clinical Research Plan of SHDC","award":["SHDC2024CRI046"],"award-info":[{"award-number":["SHDC2024CRI046"]}]},{"name":"Clinical Research Plan of SHDC","award":["SHDC2020CR6024"],"award-info":[{"award-number":["SHDC2020CR6024"]}]},{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2023YFC2307300&2023YFC2307301"],"award-info":[{"award-number":["2023YFC2307300&2023YFC2307301"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai 2020 \"Science and technology innovation action plan\" technological innovation fund","award":["20Z11900500"],"award-info":[{"award-number":["20Z11900500"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-11605-y","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:43:56Z","timestamp":1759164236000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Bedaquiline combined with clofazimine as salvage therapy for 11 patients with nontuberculous mycobacterial lung disease"],"prefix":"10.1186","volume":"25","author":[{"given":"Lan","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xubin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoling","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoyan","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Sha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"11605_CR1","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.5588\/ijtld.14.0120","volume":"18","author":"SK Brode","year":"2014","unstructured":"Brode SK, Daley CL, Marras TK. The epidemiologic relationship between tuberculosis and non-tuberculous mycobacterial disease: a systematic review. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. 2014;18:1370\u20137.","journal-title":"Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis"},{"key":"11605_CR2","doi-asserted-by":"publisher","first-page":"1900250","DOI":"10.1183\/13993003.00250-2019","volume":"54","author":"S Cowman","year":"2019","unstructured":"Cowman S, van Ingen J, Griffith DE, Loebinger MR. Non-tuberculous mycobacterial pulmonary disease. Eur Respir J. 2019;54:1900250.","journal-title":"Eur Respir J"},{"issue":"Suppl 4","key":"11605_CR3","doi-asserted-by":"publisher","first-page":"S199","DOI":"10.1093\/infdis\/jiaa354","volume":"222","author":"CL Daley","year":"2020","unstructured":"Daley CL, Winthrop KL. Mycobacterium avium complex: addressing gaps in diagnosis and management. J Infect Dis. 2020;222(Suppl 4):S199-211.","journal-title":"J Infect Dis"},{"key":"11605_CR4","doi-asserted-by":"publisher","first-page":"6758","DOI":"10.1128\/AAC.01240-16","volume":"60","author":"SM Moon","year":"2016","unstructured":"Moon SM, Park HY, Kim S-Y, Jhun BW, Lee H, Jeon K, et al. Clinical characteristics, treatment outcomes, and resistance mutations associated with macrolide-resistant Mycobacterium avium complex lung disease. Antimicrob Agents Chemother. 2016;60:6758\u201365.","journal-title":"Antimicrob Agents Chemother"},{"key":"11605_CR5","doi-asserted-by":"publisher","first-page":"e01206","DOI":"10.1128\/AAC.01206-17","volume":"61","author":"JG Pasipanodya","year":"2017","unstructured":"Pasipanodya JG, Ogbonna D, Ferro BE, Magombedze G, Srivastava S, Deshpande D, et al. Systematic review and meta-analyses of the effect of chemotherapy on pulmonary Mycobacterium abscessus outcomes and disease recurrence. Antimicrob Agents Chemother. 2017;61:e01206-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"11605_CR6","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1128\/AAC.00052-06","volume":"50","author":"B Ji","year":"2006","unstructured":"Ji B, Lefran\u00e7ois S, Robert J, Chauffour A, Truffot C, Jarlier V. In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrob Agents Chemother. 2006;50:1921\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"11605_CR7","doi-asserted-by":"publisher","first-page":"4202","DOI":"10.1128\/AAC.00181-07","volume":"51","author":"E Huitric","year":"2007","unstructured":"Huitric E, Verhasselt P, Andries K, Hoffner SE. In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother. 2007;51:4202\u20134.","journal-title":"Antimicrob Agents Chemother"},{"key":"11605_CR8","doi-asserted-by":"publisher","first-page":"e02627","DOI":"10.1128\/AAC.02627-16","volume":"61","author":"Y Pang","year":"2017","unstructured":"Pang Y, Zheng H, Tan Y, Song Y, Zhao Y. Vitro activity of bedaquiline against nontuberculous mycobacteria in China. Antimicrob Agents Chemother. 2017;61:e02627\u201316.","journal-title":"Antimicrob Agents Chemother"},{"key":"11605_CR9","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1099\/jmm.0.000537","volume":"66","author":"DA Aguilar-Ayala","year":"2017","unstructured":"Aguilar-Ayala DA, Cnockaert M, Andr\u00e9 E, Andries K, Gonzalez-Y-Merchand JA, Vandamme P, et al. In vitro activity of bedaquiline against rapidly growing nontuberculous mycobacteria. J Med Microbiol. 2017;66:1140\u20133.","journal-title":"J Med Microbiol"},{"key":"11605_CR10","doi-asserted-by":"publisher","first-page":"1601969","DOI":"10.1183\/13993003.01969-2016","volume":"49","author":"S Vesenbeckh","year":"2017","unstructured":"Vesenbeckh S, Sch\u00f6nfeld N, Krieger D, Bettermann G, Bauer TT, R\u00fcssmann H, et al. Bedaquiline as a potential agent in the treatment of M. intracellulare and M. avium infections. Eur Respir J. 2017;49:1601969.","journal-title":"Eur Respir J"},{"key":"11605_CR11","doi-asserted-by":"publisher","first-page":"e01919","DOI":"10.1128\/AAC.01919-18","volume":"63","author":"BA Brown-Elliott","year":"2019","unstructured":"Brown-Elliott BA, Wallace RJ. Vitro susceptibility testing of bedaquiline against Mycobacterium abscessus complex. Antimicrob Agents Chemother. 2019;63:e01919\u201318.","journal-title":"Antimicrob Agents Chemother"},{"key":"11605_CR12","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.jmii.2017.05.001","volume":"51","author":"C-C Huang","year":"2018","unstructured":"Huang C-C, Wu M-F, Chen H-C, Huang W-C. In vitro activity of aminoglycosides, clofazimine, d-cycloserine and dapsone against 83 Mycobacterium avium complex clinical isolates. J Microbiol Immunol Infect. 2018;51:636\u201343.","journal-title":"J Microbiol Immunol Infect"},{"key":"11605_CR13","doi-asserted-by":"publisher","first-page":"e00072","DOI":"10.1128\/AAC.00072-18","volume":"62","author":"J Luo","year":"2018","unstructured":"Luo J, Yu X, Jiang G, Fu Y, Huo F, Ma Y, et al. Vitro activity of Clofazimine against nontuberculous mycobacteria isolated in beijing, China. Antimicrob Agents Chemother. 2018;62:e00072\u201318.","journal-title":"Antimicrob Agents Chemother"},{"key":"11605_CR14","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.chest.2020.07.040","volume":"159","author":"N Kwak","year":"2021","unstructured":"Kwak N, Whang J, Yang JS, Kim TS, Kim SA, Yim J-J. Minimal inhibitory concentration of Clofazimine among clinical isolates of nontuberculous mycobacteria and its impact on treatment outcome. Chest. 2021;159:517\u201323.","journal-title":"Chest"},{"key":"11605_CR15","doi-asserted-by":"publisher","first-page":"e02052","DOI":"10.1128\/AAC.02052-16","volume":"61","author":"B Yang","year":"2017","unstructured":"Yang B, Jhun BW, Moon SM, Lee H, Park HY, Jeon K, et al. Clofazimine-containing regimen for the treatment of Mycobacterium abscessus lung disease. Antimicrob Agents Chemother. 2017;61:e02052-16.","journal-title":"Antimicrob Agents Chemother"},{"key":"11605_CR16","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.chest.2017.04.175","volume":"152","author":"SL Martiniano","year":"2017","unstructured":"Martiniano SL, Wagner BD, Levin A, Nick JA, Sagel SD, Daley CL. Safety and effectiveness of clofazimine for primary and refractory nontuberculous mycobacterial infection. Chest. 2017;152:800\u20139.","journal-title":"Chest"},{"key":"11605_CR17","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.chest.2023.11.038","volume":"165","author":"SMH Zweijpfenning","year":"2024","unstructured":"Zweijpfenning SMH, Aarnoutse R, Boeree MJ, Magis-Escurra C, Stemkens R, Geurts B, et al. Safety and efficacy of clofazimine as an alternative for rifampicin in Mycobacterium avium complex pulmonary disease treatment: outcomes of a randomized trial. Chest. 2024;165:1082\u201392.","journal-title":"Chest"},{"key":"11605_CR18","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1093\/jac\/dky526","volume":"74","author":"MM Ruth","year":"2019","unstructured":"Ruth MM, Sangen JJN, Remmers K, Pennings LJ, Svensson E, Aarnoutse RE, et al. A bedaquiline\/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria. J Antimicrob Chemother. 2019;74:935\u201343.","journal-title":"J Antimicrob Chemother"},{"key":"11605_CR19","doi-asserted-by":"publisher","first-page":"2000535","DOI":"10.1183\/13993003.00535-2020","volume":"56","author":"CL Daley","year":"2020","unstructured":"Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ, Andrejak C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline. Eur Respir J. 2020;56:2000535.","journal-title":"Eur Respir J"},{"key":"11605_CR20","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1378\/chest.14-2764","volume":"148","author":"JV Philley","year":"2015","unstructured":"Philley JV, Wallace RJ, Benwill JL, Taskar V, Brown-Elliott BA, Thakkar F, et al. Preliminary results of bedaquiline as salvage therapy for patients with nontuberculous mycobacterial lung disease. Chest. 2015;148:499\u2013506.","journal-title":"Chest"},{"key":"11605_CR21","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01096-18","volume":"57","author":"Y Xu","year":"2019","unstructured":"Xu Y, Liang B, Du C, Tian X, Cai X, Hou Y, et al. Rapid identification of clinically relevant Mycobacterium species by multicolor melting curve analysis. J Clin Microbiol. 2019;57:e01096\u201318.","journal-title":"J Clin Microbiol"},{"key":"11605_CR22","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1093\/jac\/dkad372","volume":"79","author":"S Omar","year":"2024","unstructured":"Omar S, Whitfield MG, Nolan MB, Ngom JT, Ismail N, Warren RM, et al. Bedaquiline for treatment of non-tuberculous mycobacteria (NTM): a systematic review and meta-analysis. J Antimicrob Chemother. 2024;79:211\u201340.","journal-title":"J Antimicrob Chemother"},{"key":"11605_CR23","first-page":"9","volume":"103","author":"WY-K Chan","year":"2021","unstructured":"Chan WY-K, Ho P-L, To KK-W, Lam AY-L, Ho KW-Y, Lau T-W, et al. A child with acute myeloid leukemia complicated by calcaneal osteomyelitis due to Mycobacterium abscessus infection after induction chemotherapy successfully salvaged with bedaquiline and Clofazimine. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2021;103:9\u201312.","journal-title":"Int J Infect Dis IJID Off Publ Int Soc Infect Dis"},{"key":"11605_CR24","doi-asserted-by":"publisher","first-page":"944","DOI":"10.3201\/eid2703.202359","volume":"27","author":"E Gil","year":"2021","unstructured":"Gil E, Sweeney N, Barrett V, Morris-Jones S, Miller RF, Johnston VJ, et al. Bedaquiline as treatment for disseminated nontuberculous mycobacteria infection in 2 patients co-infected with HIV. Emerg Infect Dis. 2021;27:944\u20138.","journal-title":"Emerg Infect Dis"},{"key":"11605_CR25","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1186\/s12879-020-05075-7","volume":"20","author":"J Erber","year":"2020","unstructured":"Erber J, Weidlich S, Tschaikowsky T, Rothe K, Schmid RM, Schneider J, et al. Successful bedaquiline-containing antimycobacterial treatment in post-traumatic skin and soft-tissue infection by Mycobacterium fortuitum complex: a case report. BMC Infect Dis. 2020;20:365.","journal-title":"BMC Infect Dis"},{"key":"11605_CR26","doi-asserted-by":"publisher","first-page":"e02234","DOI":"10.1128\/AAC.02234-18","volume":"63","author":"A Cheng","year":"2019","unstructured":"Cheng A, Tsai Y-T, Chang S-Y, Sun H-Y, Wu U-I, Sheng W-H, et al. Vitro synergism of Rifabutin with clarithromycin, imipenem, and Tigecycline against the Mycobacterium abscessus complex. Antimicrob Agents Chemother. 2019;63:e02234\u201318.","journal-title":"Antimicrob Agents Chemother"},{"key":"11605_CR27","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jgar.2021.06.002","volume":"26","author":"B Hajikhani","year":"2021","unstructured":"Hajikhani B, Nasiri MJ, Hosseini SS, Khalili F, Karimi-Yazdi M, Hematian A, et al. Clofazimine susceptibility testing of Mycobacterium avium complex and Mycobacterium abscessus: a meta-analysis study. J Glob Antimicrob Resist. 2021;26:188\u201393.","journal-title":"J Glob Antimicrob Resist"},{"issue":"Suppl 2","key":"11605_CR28","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1136\/thoraxjnl-2017-210927","volume":"72","author":"CS Haworth","year":"2017","unstructured":"Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, et al. British thoracic society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax. 2017;72(Suppl 2):ii1\u201364.","journal-title":"Thorax"},{"key":"11605_CR29","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1128\/JCM.02087-16","volume":"55","author":"DC Alexander","year":"2017","unstructured":"Alexander DC, Vasireddy R, Vasireddy S, Philley JV, Brown-Elliott BA, Perry BJ, et al. Emergence of mmpT5 variants during bedaquiline treatment of Mycobacterium intracellulare lung disease. J Clin Microbiol. 2017;55:574\u201384.","journal-title":"J Clin Microbiol"},{"key":"11605_CR30","doi-asserted-by":"publisher","unstructured":"Zweijpfenning SMH, Schildkraut JA, Coolen JPM, Ruesen C, Koenraad E, Janssen A, et al. Failure with acquired resistance of an optimised bedaquiline-based treatment regimen for pulmonary Mycobacterium avium complex disease. Eur Respir J. 2019;54(1):1900118. https:\/\/doi.org\/10.1183\/13993003.00118-2019.","DOI":"10.1183\/13993003.00118-2019"},{"key":"11605_CR31","doi-asserted-by":"publisher","first-page":"e00544","DOI":"10.1128\/AAC.00544-18","volume":"62","author":"Y Chen","year":"2018","unstructured":"Chen Y, Chen J, Zhang S, Shi W, Zhang W, Zhu M, et al. Novel mutations associated with clofazimine resistance in Mycobacterium abscessus. Antimicrob Agents Chemother. 2018;62:e00544-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"11605_CR32","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01316-18","volume":"63","author":"M Richard","year":"2019","unstructured":"Richard M, Guti\u00e9rrez AV, Viljoen A, Rodriguez-Rincon D, Roquet-Baneres F, Blaise M, et al. Mutations in the MAB_2299c TetR regulator confer cross-resistance to clofazimine and bedaquiline in Mycobacterium abscessus. Antimicrob Agents Chemother. 2019;63:e01316\u201318.","journal-title":"Antimicrob Agents Chemother"},{"key":"11605_CR33","first-page":"176","volume":"107","author":"A Meybeck","year":"2021","unstructured":"Meybeck A, Tetart M, Baclet V, Alcaraz I, Blondiaux N, Peytavin G, et al. A disseminated Mycobacterium marinum infection in a renal transplant HIV-infected patient successfully treated with a bedaquiline-containing antimycobacterial treatment: A case report. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2021;107:176\u20138.","journal-title":"Int J Infect Dis IJID Off Publ Int Soc Infect Dis"},{"key":"11605_CR34","doi-asserted-by":"publisher","unstructured":"Daley CL. Mycobacterium avium complex disease. Microbiol Spectr. 2017;5(2):10.1128\/microbiolspec.tnmi7-0045-2017. https:\/\/doi.org\/10.1128\/microbiolspec.TNMI7-0045-2017.","DOI":"10.1128\/microbiolspec.TNMI7-0045-2017"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11605-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11605-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11605-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T01:03:56Z","timestamp":1759194236000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-11605-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11605"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11605-y","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"6 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial was approved by Shanghai Pulmonary Hospital (L20-348Y). Informed consents were obtained from the participants before enrollment. All experimental protocols adhered to the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1203"}}